Skip Navigation

U.S. Department of Health & Human ServicesLink to www.hhs.gov
OMH Home

En Español
The Office of Minority Health (Phone: 1-800-444-6472)
About OMH
Our Services
Campaigns/Initiatives
Press Releases
Calendar
Employment
Publications
Federal Clearinghouses
Research
OPHS Home
Image of a person asking a questionNeed Help?
Contact Us

HIV/AIDS Observance Days Icon
Click for more information

AIDS.gov web site logo
AIDS.gov for Federal HIV/AIDS Information
Join Our Mailing ListJoin Our Mailing List
Click to sign up


OMH Content

Food and Drug Administration's (FDA) Office of Orphan Products Development (OPD) Grant

These grant awards will support clinical trials on the safety and effectiveness of products for rare diseases and conditions. These studies are intended to provide acceptable data to the FDA that will substantially contribute to the approval of new products, or new indications for already marketed products.

The receipt date for FY 2008 is February 7, 2007

The Food and Drug Administration's (FDA) Office of Orphan Products Development (OPD) is pleased to announce the availability of funds for fiscal year (FY) 2008 grant awards to support clinical trials on the safety and effectiveness of products for rare diseases and conditions. Contingent on availability of FY 2007 and FY 2008 funds, it is anticipated that $14.2 million will be available for new applications, competing awards, and non competing continuation awards. The next due date for receipt of FY 2008 grant applications is February 7, 2007.

These studies are intended to provide acceptable data to the FDA that will substantially contribute to the approval of new products, or new indications for already marketed products. In the FDA OPD grants program, products for rare diseases and conditions (orphan products) are defined as drugs, biologics, medical devices, and medical foods indicated to treat or diagnose a rare disease or condition with a prevalence of fewer than 200,000 people in the United States.

A complete text of the FDA request for applications (RFA) is available in the Federal Register (FR) notice, dated December 19, 2005, or at www.fda.gov/orphan/grants. FDA will support the clinical studies covered by this notice under section 301 of the Public Service Act (42 U.S.C. 241). Regarding the administrative and financial management aspects of this notice, please contact:

Usha Ganti, Supervisory Grants Management Specialist
Division of Contracts and Grants Management (HFA-500)
FDA
5600 Fishers Lane
Rockville, Maryland 20857
301-827-7182
e-mail: usha.ganti@fda.hhs.gov

Regarding the program aspects of this notice, please contact:
Debra Y. Lewis, O.D., Director, OPD Grant Program (HF-35)
FDA
5600 Fishers Lane
Rockville, Maryland 20857
301-827-0059
e-mail: debra.lewis@fda.hhs.gov

To request a copy of the December 19, 2005 FR notice, please phone the OPD office at 301-827-3666/1-800-300-7469 or send a fax request to 301-827-0017.

Information by E-Mail or Web site

Subscribers to the FDA orphan products information listserv receive relevant Federal Register notices, up-to-date lists of orphan designations and approvals, and newsworthy items of interest to the orphan products community. Subscribe at: http://list.nih.gov/archives/orphanprodinfo.html

For more information regarding the Office of Orphan Products Development please visit the following website: http://www.fda.gov/orphan



Content Last Modified: 10/25/2006 9:43:00 AM
OMH Home  |  HHS Home  |  USA.gov  |  Disclaimer  |  Privacy Policy  |  HHS FOIA  |  Accessibility  |  Site Map  |  Contact Us  |  File Formats

Office of Minority Health
Toll Free: 1-800-444-6472 / Fax: 301-251-2160
Email: info@omhrc.gov

Provide Feedback